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Introduction: Epidermal growth factor receptor (EGFR) mutations 
in non–small-cell lung cancer predict response to tyrosine kinase 
inhibitors. The frequency of EGFR mutations is ethnicity-depen-
dent, with a higher proportion in Asian populations than in whites. 
The prevalence of these mutations among North African patients is 
unknown.The objective of this study was to report the frequency and 
spectrum of EGFR mutations in a group of Moroccan patients with 
lung adenocarcinoma (AC).
Methods: Tumor specimens from 137 Moroccan patients with lung 
AC were selected to determine frequency and spectrum of EGFR 
mutations. Mutation detection techniques were polymerase chain 
reaction amplification and sequencing of exons 18, 19, 20, and 21.
Results: The overall frequency of the EGFR mutation was 21%. 
Mutations were mainly detected in the exon 19 (69%), followed by 
exon 21 (21%) and exon 20 (7%), whereas mutations in the exon 
18 were rare (3%). EGFR mutation rate was significantly higher in 
women and in never smokers.
Conclusion: Some one fifth of lung AC tumors in Moroccan patients 
harbor EGFR mutations. This mutation frequency is higher than that 
found in whites but lower than in Asian population. Further studies, 
in larger numbers of patients, are needed to confirm these findings.
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(J Thorac Oncol. 2013;8: 1212-1214)
Epidermal growth factor receptor (EGFR) is a transmem-brane glycoprotein that is a member of the protein kinase 
superfamily. Binding of ligand to the extracellular domain 
of EGFR leads to receptor dimerization and activation of 
signaling pathways associated with cell growth and neoplastic 
progression.1
EGFR mutations reported in non–small-cell lung cancer 
(NSCLC) are potential therapeutic targets leading to improved 
response and survival with tyrosine kinase inhibitors (TKIs) 
in patients carrying such mutations.2 These mutations are 
more common in patients with adenocarcinoma (AC), women, 
and no history of smoking.2,3 The frequency of EGFR muta-
tions is also ethnicity-dependent, with a higher proportion in 
Asian populations than in whites.4–6 However, such informa-
tion is still lacking in some other races, such as North African 
patients.
The most common mutations associated with sensitivity 
to EGFR-TKIs include exon 19 deletions and the L858R point 
mutation in exon 21. Together, these two mutations account 
for nearly 90% of all EGFR mutations in NSCLC.7,8
The main goal of this study was to report the frequency 
and spectrum of EGFR mutations in an unselected group of 
Moroccan patients with lung AC. In addition, we examined 
the relationship between the mutations and several parame-
ters, including sex and smoking status.
PATIENTS AND METHODS
Data of all lung AC samples were collected from 
four pathology laboratories in Morocco between November 
2010 and August 2012. All of these laboratories outsource 
EGFR mutation testing to the Molecular Biology Laboratory 
at Georges Pompidou European Hospital (Paris, France) and 
perform more than 90% of all tests requested in Morocco.
Genomic DNA was isolated from formalin-fixed paraf-
fin-embedded tumor tissues. Genetic analysis of the EGFR gene 
was performed by TaqMan (Roche Molecular Diagnostics, 
Basel, Switzerland) polymerase chain reaction assay and direct 
sequencing of exons 18, 19, 20, and 21. All tumor specimens 
were biopsy samples.
Only Moroccan patients with advanced lung AC were 
included. All EGFR tests that were outsourced from the pathol-
ogy labs were considered for this study. The histologic diag-
nosis of AC was verified using the pathology report provided 
by participating laboratories. Never smokers were defined as 
individuals who reported smoking fewer than 100 cigarettes 
in their lifetime.
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The potential associations of EGFR mutation with age, 
sex, and smoking status were analyzed using χ2 statistics. 
Means of age were compared using the t test. A p value less than 
0.05 was considered statistically significant. All analyses were 
performed using SPSS (version 20; SPSS Inc., Chicago, IL).
RESULTS
One hundred thirty-seven lung ACs from Moroccan 
patients were collected. The study population consisted of 91 
men (66%) and 46 women (44%), with a median age of 59 
years (range, 37–87 years). The demographic characteristics 
of the patients are provided in Table 1.
A total of 29 EGFR mutations were found in this series 
of 137 patients (21%). The most frequent EGFR mutation was 
detected in exon 19 (20 patients; 69%), followed by exon 21 
(6 patients; 21%). There were two mutations in exon 18 (7%) 
and only one in exon 20 (3%).
In the population with EGFR mutations, the frequency 
of women was significantly higher than that found in patients 
with wild-type EGFR (76% versus 22%; p < 0.0001). The 
frequency of never smokers in patients with tumors having 
EGFR mutations was significantly higher than that observed 
in patients without mutations (83% versus 31%; p < 0.0001). 
The mean age did not differ between the two groups (Table 2).
DISCUSSION
Lung cancer is one of the most common cancers in 
Morocco and in the world, and is the leading cause of can-
cer mortality in both men and women.9 EGFR mutations are 
currently used as predictive markers of clinical response to 
EGFR-TKIs, with 70% to 80% of patients deriving substantial 
benefit from these targeted therapies.2 This shows the clinical 
relevance of EGFR mutational status for therapeutic decision 
making in patients with advanced NSCLC.
In the present series, EGFR mutations were identified in 
29 of 137 Moroccan patients (21%). To the best of our knowl-
edge, this study represents the first study to date reporting the 
EGFR mutation rate in North African and Arab populations.
Some previous studies have demonstrated a genetic 
divergence of EGFR mutation rates according to ethnic-
ity.4–6,10,11 Indeed, the EGFR mutation rate in East-Asian 
patients (39%–43%) is much higher than that of the white 
population (11%–13%) whereas some races, such South-
Asian, have an intermediate rate (23%). EGFR mutation 
frequency in Moroccan patients, as reported in this study, is 
higher than that found in whites but lower than in Asians. This 
rate is in the same order of magnitude as that reported in some 
developing countries, like Bangladesh (Table 3).
In ACs, the majority of mutations have been identified 
in exons 18 to 21, which encode the tyrosine kinase domain. 
Over 90% of the clinically important EGFR mutations are 
either a small deletion in exon 19 or a point mutation in exon 
21.7,8 Several studies have reported similar distribution of exon 
19 mutation (35%–50%) and exon 21 mutation (33%–48%) 
between Asian and non-Asian patients6–8,12 (Table 4).
In our subjects, EGFR mutations were mainly detected in 
the exon 19 (69%) followed by exon 21 (21%) and exon 20 (7%), 
whereas mutations in the exon 18 were rare (3%). Therefore, 
Moroccan patients may have a higher rate of exon 19 mutation 
and lower frequency of exon 21 mutation than other races.
Mutation type status may have clinical relevance because 
some studies have shown that response to EGFR-TKIs varies 
TABLE 1.  Demographic Characteristics of the Study 
Population
Characteristics
All Patients (n = 137)
No %
Age (yr)
 Median 59
 Range 37–87
Sex
 Male 91 (66%)
 Female 46 (44%)
Smoking history
 Never 58 (42%)
 Ever 79 (58%)
Histology
 Adenocarcinoma 137 (100%)
Stage at diagnosis
 IV 137 (100%)
TABLE 2.  Patient Characteristics by EGFR Mutation Status
Characteristics
EGFR Mutations EGFR Wild Type
p(n = 29) (n = 108)
Mean age at diagnosis (yr) 60 60 0.98*
Sex
 Male 7 (24%) 84 (78%)
 Female 22 (76%) 24 (22%) <0.0001**
Smoking history
 Ever 5 (17%) 74 (69%)
 Never 24 (83%) 34 (31%) <0.0001**
*p value calculated by t test.
**p value calculated by χ2 test.
EGFR, epidermal growth factor receptor.
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according to the mutation type. Rosell et al.13 have reported 
an increased response to EGFR-TKIs in patients with exon 
19 deletions versus exon 21 L858R mutation (p = 0.001). In 
addition, Jackman et al.14 found that patients with exon 19 
deletions treated with EGFR-TKIs had a median survival of 
38 months compared with only 17 months in those with the 
exon 21 point mutation. Thus, the high rate of exon 19 muta-
tion in Moroccan population may result in a higher frequency 
of response to treatment.
In the present study, the EGFR mutation rate was sig-
nificantly higher in women and in never smokers. These 
results are in keeping with those reported by other studies.2,3 
However, it is now admitted that the presence of EGFR muta-
tion predicts the likelihood of response to EGFR-TKI treat-
ment more than clinical characteristics such sex and smoking 
history.2 Thus, only EGFR mutation status may truly underlie 
sensitivity to treatment.
In conclusion, the present study revealed that EGFR 
mutation rate in Moroccan patients lies between that of Asian 
and white populations. The high rate of exon 19 mutation in 
this study may result in a higher frequency of response to 
EGFR-TKIs. Further studies, in larger numbers of patients, 
are needed to confirm these findings.
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TABLE 3.  Frequency of EGFR Mutation by Race
Study Race EGFR Mutation (%)
Tanaka et al.4 East Asian (Japan) 104/242 (43%)
Choi et al.5 East Asian (Korea) 203/521 (39%)
Rahman et al.11 South Asian (Bangladesh) 14/61 (23%)
Castro et al.6 White 29/216 (13%)
Smits et al.10 White 66/620 (11%)
This study North African 29/137 (21%)
EGFR, epidermal growth factor receptor.
TABLE 4.  Frequency of EGFR Mutation Types by Race
Study Race
Exon 19  
Deletion (%)
Exon 21
L858R Mutation 
(%)
Huang et al.7 Asian 35 48
Shigematsu et al.8 American 44 41
Castro et al.6 White 39 33
De Mello et al.12 White 50 45
This study North African 69 21
EGFR, epidermal growth factor receptor.
